Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 6—June 2020
Research

Failures of 13-Valent Conjugated Pneumococcal Vaccine in Age-Appropriately Vaccinated Children 2–59 Months of Age, Spain

Sergi HernándezComments to Author , Fernando Moraga-Llop, Alvaro Díaz, Mariona F. de Sevilla, Pilar Ciruela, Carmen Muñoz-Almagro, Gemma Codina, Magda Campins, Juan José García-García, Cristina Esteva, Conchita Izquierdo, Sebastià González-Peris, Johanna Martínez-Osorio, Sonia Uriona, Luis Salleras, and Ángela Domínguez
Author affiliations: Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Barcelona, Spain (S. Hernández, P. Ciruela, C. Izquierdo); Hospital Universitari Vall d’Hebron, Barcelona (F. Moraga-Llop, M. Campins, S. González-Peris); Hospital de Nens, Barcelona (A. Díaz); Hospital Sant Joan de Déu Barcelona, Barcelona (M.F. de Sevilla, C. Muñoz-Almagro, J.J. García-García, C. Esteva, J. Martínez-Osorio); Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain (M.F. de Sevilla, C. Muñoz-Almagro, J.J. García-García); CIBER de Epidemiología y Salud Pública, Madrid, Spain (P. Ciruela, J.J. García-García, C. Esteva, L. Salleras, Á. Domínguez); Universitat Internacional de Catalunya, Barcelona (C. Muñoz-Almagro); Vall d’Hebron Institut de Recerca, Barcelona (M. Campins, S. Uriona); Universitat de Barcelona, Barcelona (L. Salleras, Á. Domínguez)

Main Article

Table 1

Characteristics of age-appropriately vaccinated patients 2–59 months of age with invasive pneumococcal disease caused by PCV13 serotypes, Catalonia, Spain, 2012–2016*

Pt no.
Age, mo/sex
Year
Age at vaccination
Schedule
Clinical manifestation
Complications
Outcome
DT
Ser
Vaccine schedule
1
19/F
2012
12 mo
1
Complicated pneumonia
Pleural effusion
Cured
PCR
19A
UC
2
15/M
2012
3 ,5 mo†
2 + 0
Complicated pneumonia
Empyema, pneumothorax
Cured
Culture, PCR
19A
UC
3
15/F
2012
2, 5, 8 mo
3 + 0
Complicated pneumonia
Empyema, necrotizing pneumonia, bronchoalveolar fistula, pneumothorax
Bronchopleural fistula
PCR
3
UC
4
23/M
2012
17 mo
1
Uncomplicated pneumonia

Cured
Culture
1
UC
5
24/M
2012
2, 4, 6, 18 mo
3 + 1
Complicated pneumonia
Empyema
Cured
PCR
19A
C
6
24/M
2012
12, 21 mo
2
Complicated pneumonia
Empyema
Cured
PCR
3
C
7
21/M
2012
3, 5, 7, 15 mo
3 + 1
Complicated pneumonia
Empyema
Cured
PCR
3
C
8
38/M
2012
30 mo
1
Bacteraemic
mastoiditis
Epidural abscess, sigmoid sinus thrombosis
Hydrocephalus
PCR
3
C
9
9/F
2013
2, 3, 4 mo
3 + 0
Complicated pneumonia
Necrotizing pneumonia
Cured
PCR
19A
UC
10
12/M
2013
2, 4, 6 mo
3 + 0
Complicated pneumonia
Empyema, necrotizing pneumonia
Cured
PCR
6B
UC
11
50/F
2013
25 mo
1
Complicated pneumonia
Empyema
Cured
PCR
3
C
12
34/M
2013
3, 6, 9, 15 mo
3 + 1
Complicated pneumonia
Empyema, pneumothorax, bronchopleural fistula
Cured
Culture, PCR
3
C
13
15/M
2014
2, 4, 7 mo
3 + 0
Osteoarticular
infection

Cured
Culture
19A
UC
14
43/M
2014
12, 15 mo
2
Complicated pneumonia
Empyema, necrotizing pneumonia, bronchopleural fistula
Cured
PCR
3
C
15
44/F
2014
3, 5, 7, 20 mo
3 + 1
Complicated pneumonia
Empyema
Cured
PCR
3
C
16
25/F
2015
2, 4, 6, 14 mo
3 + 1
Complicated pneumonia
Pleural effusion
Cured
Culture
14
C
17
29/M
2015
3, 5, 7, 18 mo
3 + 1
Complicated pneumonia
Necrotizing pneumonia
Cured
PCR
3
C
18
51/M
2015
2, 4, 6, 16 mo
3 + 1
Complicated pneumonia
Empyema
Cured
PCR
3
C
19
49/F
2015
12,14 mo
2
Complicated pneumonia
Empyema
Cured
PCR
3
C
20
54/F
2015
3, 5, 7,17 ​​mo
3 + 1
Complicated pneumonia
Empyema
Cured
PCR
3
C
21
58/M
2016
14, 16 mo
2
Complicated pneumonia
Empyema, necrotizing pneumonia
Pneumatocele
PCR
3
C
22
35/M
2016
2, 5, 9, 18 mo
3 + 1
Complicated pneumonia
Empyema, necrotizing pneumonia
Cured
PCR
3
C
23
41/M
2016
3, 4, 7, 16 mo
3 + 1
Complicated pneumonia
Necrotizing pneumonia
Cured
PCR
3
C
24 23/M 2016 3, 5, 6, 15 mo 3 + 1 Complicated pneumonia Pleural effusion Cured PCR 3 C

*C, completed; DT, diagnostic technique; Pt, patient; Ser, serotype; UC, uncompleted.
†Patient resident in Andorra (routine immunization schedule 2+1) and transferred to a participating hospital.

Main Article

Page created: May 18, 2020
Page updated: May 18, 2020
Page reviewed: May 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external